| scholarly article | Q13442814 |
| P50 | author | Margaret A Fischl | Q63847562 |
| Ann C Collier | Q87874619 | ||
| Paul E Sax | Q91303052 | ||
| P2093 | author name string | Camlin Tierney | |
| Eric S Daar | |||
| David Katzenstein | |||
| Ronald J Bosch | |||
| Christina M Lalama | |||
| Maya Balamane | |||
| Katie Mollan | |||
| AIDS Clinical Trials Group Study A5202 Team | |||
| P2860 | cites work | Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART | Q21563427 |
| Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies | Q24597052 | ||
| Use of a high resolution melting (HRM) assay to compare gag, pol, and env diversity in adults with different stages of HIV infection | Q28743210 | ||
| Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy | Q33565604 | ||
| Effect of early versus deferred antiretroviral therapy for HIV on survival | Q33789114 | ||
| Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America | Q33853922 | ||
| Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients | Q33875048 | ||
| Stochastic interplay between mutation and recombination during the acquisition of drug resistance mutations in human immunodeficiency virus type 1 | Q34092679 | ||
| A Multicenter, Open Labeled, Randomized, Phase III Study Comparing Lopinavir/Ritonavir Plus Atazanavir to Lopinavir/Ritonavir Plus Zidovudine and Lamivudine in Naive HIV-1-Infected Patients: 48-Week Analysis of the LORAN Trial | Q35012981 | ||
| Coordinate linkage of HIV evolution reveals regions of immunological vulnerability | Q35105172 | ||
| Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection | Q35127808 | ||
| Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results | Q35214141 | ||
| Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic | Q35826795 | ||
| Designing a genome-based HIV incidence assay with high sensitivity and specificity | Q35868993 | ||
| Recombination favors the evolution of drug resistance in HIV-1 during antiretroviral therapy | Q36091918 | ||
| Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. | Q36198650 | ||
| HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes | Q36905669 | ||
| Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes | Q37189025 | ||
| Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials | Q37228748 | ||
| Update of the Drug Resistance Mutations in HIV-1. | Q37357605 | ||
| A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors | Q37387866 | ||
| Class-sparing regimens for initial treatment of HIV-1 infection | Q37454026 | ||
| Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AAC | Q41752733 | ||
| Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study | Q46414306 | ||
| Error Detecting and Error Correcting Codes | Q55871133 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | virology | Q7215 |
| ritonavir | Q422618 | ||
| efavirenz | Q422645 | ||
| atazanavir | Q423467 | ||
| P304 | page(s) | 1920-1930 | |
| P577 | publication date | 2012-11-12 | |
| P1433 | published in | Journal of Infectious Diseases | Q4051141 |
| P1476 | title | HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status | |
| P478 | volume | 206 |
| Q46600089 | Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants |
| Q40039995 | Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors |
| Q28545866 | Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis |
| Q30384060 | Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study |
| Q28271593 | HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing |
| Q30245693 | HIV-1 drug resistance and resistance testing |
| Q42649793 | High rate of HIV-1 drug resistance in treatment failure patients in Taiwan, 2009-2014. |
| Q41926589 | Human Immunodeficiency Virus Type 1 Drug Resistance Mutations Update |
| Q37305622 | Human Immunodeficiency Virus-1 Sequence Changes and Drug Resistance Mutation Among Virologic Failures of Lopinavir/Ritonavir Monotherapy: AIDS Clinical Trials Group Protocol A5230. |
| Q34289476 | Phylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viraemia |
| Q90438789 | Selection analyses of paired HIV-1 gag and gp41 sequences obtained before and after antiretroviral therapy |
| Q38756649 | Strategic use of dual regimens of boosted protease inhibitors plus maraviroc in poorly adherent subjects in view of long-acting drugs: A retrospective study |
Search more.